Manas Mishra has covered the healthcare and pharmaceuticals sector since 2017. He joined Norstella from Reuters, where he spent 8 years covering a range of breaking news stories ranging from vaccine development during the peak of the COVID-19 pandemic, to the killing of UnitedHealthcare CEO Brian Thompson. Manas was the Editor-in-Charge of the Bangalore health and pharmaceuticals team at Reuters between 2022-2025. When not looking for stories, Manas enjoys attending rock and metal concerts, swimming and reading science fiction.
Latest from Manas Mishra
While China is already a key market for AstraZeneca, the UK-based firm has announced a $15bn investment commitment in the country to boost its capabilities in cell therapy and radioconjugates.
Tenpoint expects to launch its Yuvezzi eye drops in early Q2, where it will compete with other rivals such as LENZ’s Vizz, as well as more traditional options such as glasses and lenses.
Bayer is the latest company seeking compensation from COVID-19 vaccine manufacturers for allegedly infringing patents.
FDA draft guidance formalizes 2024 advisory committee recommendations and would allow earlier, more precise indicators of cancer clearance in multiple myeloma to support accelerated approval and reduce reliance on overall response rate.
Just a week after the J.P. Morgan Healthcare conference, GSK’s first buyout of 2026 is focused on anti‑IgE antibody, ozureprubart, which is in Phase II development for prophylactic protection against food allergens.
Clinical Data Readout: A mixed Phase III study in relapsed/refractory DLBCL complicates AbbVie and Genmab’s bid to expand Epkinly beyond its accelerated approval.